The notion that HER2+ tumors do not represent a separate subtype but a wider biological spectrum was strengthened by a recent study identifying four different subtypes of HER2+ breast carcinomas based on gene expression signatures (Ferrari et al., 2016). Here, ERBB2 is linked to breast carcinoma.